NCT06287918View on ClinicalTrials.gov

A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

June 30, 2028

Conditions
Solid Tumors With FGFR2 Alterations, Adult
Interventions
DRUG

3HP-2827

3HP-2827 will be administered orally once daily in 28-day cycles.

Trial Locations (2)

77030

The University of Texas MD Anderson Cancer Center, Houston

85054

Mayo Clinic, Phoenix

All Listed Sponsors
lead

3H (Suzhou) Pharmaceuticals Co., Ltd.

INDUSTRY